193 related articles for article (PubMed ID: 29305186)
1. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis.
Papoutsidakis N; Miller EJ; Rodonski A; Jacoby D
J Card Fail; 2018 Feb; 24(2):131-133. PubMed ID: 29305186
[No Abstract] [Full Text] [Related]
2. Case With Transthyretin Amyloid Cardiomyopathy Complicated With Rapidly Progressive Aortic Stenosis Possibly Caused by Amyloid Deposition in the Aortic Valve.
Fujimoto T; Yamano T; Miyagawa-Hayashino A; Naiki H; Ueda M; Tasaki M; Yamano M; Zen K; Numata S; Matoba S
Circ Cardiovasc Imaging; 2021 Nov; 14(11):e013357. PubMed ID: 34727706
[No Abstract] [Full Text] [Related]
3. High 99mTc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy.
Quarta CC; Obici L; Guidalotti PL; Pieroni M; Longhi S; Perlini S; Verga L; Merlini G; Rapezzi C
Amyloid; 2013 Mar; 20(1):48-51. PubMed ID: 23231421
[TBL] [Abstract][Full Text] [Related]
4. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
5. Cardiac Amyloidosis: Diagnosis and Treatment Strategies.
Tuzovic M; Yang EH; Baas AS; Depasquale EC; Deng MC; Cruz D; Vorobiof G
Curr Oncol Rep; 2017 Jul; 19(7):46. PubMed ID: 28528458
[TBL] [Abstract][Full Text] [Related]
6. Reply: could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Siontis GC; Windecker S
J Am Coll Cardiol; 2015 Jan; 65(3):313. PubMed ID: 25614435
[No Abstract] [Full Text] [Related]
7. Reply: could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Kim WK; Rolf A; Möllmann H
J Am Coll Cardiol; 2015 Jan; 65(3):312-3. PubMed ID: 25614434
[No Abstract] [Full Text] [Related]
8. Could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?
Castaño A; Bokhari S; Maurer MS
J Am Coll Cardiol; 2015 Jan; 65(3):311-2. PubMed ID: 25614433
[No Abstract] [Full Text] [Related]
9. Transthyretin Cardiac Amyloidosis Due to Homozygous Val122Ile Mutation in a Caucasian Man.
Marrero Negrín N; Medina Gil JM; García Cruz ML; Jiménez Cabrera F
Rev Esp Cardiol (Engl Ed); 2019 Dec; 72(12):1086-1088. PubMed ID: 31561982
[No Abstract] [Full Text] [Related]
10. Hereditary Transthyretin Amyloid Cardiomyopathy.
Youmans QR; Shah SJ; Khan SS
JAMA Cardiol; 2022 Feb; 7(2):236. PubMed ID: 34935856
[No Abstract] [Full Text] [Related]
11. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis.
Gallego-Delgado M; González-López E; Muñoz-Beamud F; Buades J; Galán L; Muñoz-Blanco JL; Sánchez-González J; Ibáñez B; Mirelis JG; García-Pavía P
Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):923-930. PubMed ID: 27291669
[TBL] [Abstract][Full Text] [Related]
13. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
[TBL] [Abstract][Full Text] [Related]
14. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP
Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620
[TBL] [Abstract][Full Text] [Related]
15. Days alive and outside of hospital from diagnosis of transthyretin vs. light chain cardiac amyloidosis.
Rubin J; Teruya S; Helmke S; De Los Santos J; Alvarez J; Maurer MS
Amyloid; 2019; 26(sup1):4-5. PubMed ID: 31343342
[No Abstract] [Full Text] [Related]
16. Seven factors predict a delayed diagnosis of cardiac amyloidosis.
Bishop E; Brown EE; Fajardo J; Barouch LA; Judge DP; Halushka MK
Amyloid; 2018 Sep; 25(3):174-179. PubMed ID: 30169971
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.
Gertz MA; Benson MD; Dyck PJ; Grogan M; Coelho T; Cruz M; Berk JL; Plante-Bordeneuve V; Schmidt HHJ; Merlini G
J Am Coll Cardiol; 2015 Dec; 66(21):2451-2466. PubMed ID: 26610878
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of cardiac transthyretin amyloidosis based on multimodality imaging.
Dahlem K; Michels G; Kobe C; Bunck AC; Ten Freyhaus H; Pfister R
Clin Res Cardiol; 2017 Jun; 106(6):471-473. PubMed ID: 28303323
[No Abstract] [Full Text] [Related]
19. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
[TBL] [Abstract][Full Text] [Related]
20. Amyloid Cardiomyopathy in Hereditary Transthyretin V30M Amyloidosis - Impact of Sex and Amyloid Fibril Composition.
Arvidsson S; Pilebro B; Westermark P; Lindqvist P; Suhr OB
PLoS One; 2015; 10(11):e0143456. PubMed ID: 26600306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
